Open Access Open Access  Restricted Access Subscription or Fee Access
HIV drugs

Organic molecular drugs designing for inhibition of cellular multiplication biocycle of virus for anti-HIV therapy development: A recent advances review

Bhupender S. Chhikara, Brijesh Rathi


The organic drug molecules synthesized target the biocycle of HIV at various stages. The common drug targets are fusion inhibitors, reverse transcriptase inhibitors (NRTI and NNRTIs), Integrase inhibitors and protease inhibitors. Herein is discussed the recent organic molecules designing and synthesis progress that targets these stages. The newer retroviral drugs and molecules under clinical trial discussed here include NRTIs (Festinavir (BMS-986001), amdoxovir, elvucitabine, apricitabine, racivir), NNRTIs (etravirine, rilpivirine), microbicides (UC-781 (Thiocarboxanilide), TMC-120 (Dapivirine), MIV-150), protease inhibitors (darunavir, tipranavir), fusion and entry inhibitors (enfuvirtide, sifuvirtide, AMD-070, BMS-663068, Cenicriviroc, INCB-9471, BMS-488043), CCR5 inhibitors (maraviroc, vicriviroc, PRO 140, PRO 542), CD4-receptor inhibitors (ibalizumab), integrase inhibitors (raltegravir, elvitegravir, GSK-1349572), maturation inhibitors (bevirimat), LEDGINs. Further details include progress in Gene therapy (siRNA), Vaccine development and progress in genetic and immune therapy for HIV treatment.


HIV; AIDS; HIV treatment; HIV Drugs; AIDS drugs;

Full Text:


ISSN 2348 – 1889